Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amoxicillin Pulsys NDA plans

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Advancis anticipates a second-half 2005 NDA filing for its amoxicillin Pulsys formulation, using the firm's once-a-day pulsatile delivery technology. A Phase III trial in adolescents and adults with acute pharyngitis and/or tonsillitis due to Group A streptococcal infections began dosing Oct. 15, with results expected in the first half of 2005. GlaxoSmithKline terminated development of an Augmentin Pulsys formulation, effective Dec. 15. "Advancis remains confident that pulsatile amoxicillin/clavulanate is technically and commercially viable, and will be exploring other avenues and partners. Additionally, the company believes continued progress on its pulsatile version of amoxicillin will help support future productive Pulsys collaborations," Advancis says...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS002689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel